FHIR IG analytics| Package | hl7.fhir.uv.genomics-reporting |
| Resource Type | Task |
| Id | Task-PGxRecEx01.json |
| FHIR Version | R4 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Task PGxRecEx01
Profile: Followup Recommendation
status: Requested
intent: proposal
code: Consider alternative medication
description: For clopidogrel, individuals with this diplotype are expected to have significantly reduced platelet inhibition, increased residual platelet aggregation and increased risk for adverse cardiovascular events in response to clopidogrel. Alternative antiplatelet therapy (if no contraindication) is recommended. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline- for-clopidogrel-and-cyp2c19/
for: Adam B. Everyman Male, DoB: 1951-01-20 ( Medical Record Number: m123 (use: usual, ))
reasonReference: Poor metabolizer
{
"resourceType": "Task",
"id": "PGxRecEx01",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"
]
},
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"status": "requested",
"intent": "proposal",
"code": {
"coding": [
{
"system": "http://loinc.org",
"code": "LA26421-0",
"display": "Consider alternative medication"
}
]
},
"description": "For clopidogrel, individuals with this diplotype are expected to have significantly reduced platelet inhibition, increased residual platelet aggregation and increased risk for adverse cardiovascular events in response to clopidogrel. Alternative antiplatelet therapy (if no contraindication) is recommended. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline- for-clopidogrel-and-cyp2c19/",
"for": {
"reference": "Patient/CGPatientExample01"
},
"reasonReference": {
"reference": "Observation/TxImp01",
"display": "Poor metabolizer"
}
}